Table 2.
Evaluation of neoadjuvant therapy efficacy
| Index | Evaluation | Erlotinib arm n = 12, (%) | GC arm n = 12, (%) | P value |
|---|---|---|---|---|
| RECIST | PR | 7/12 (58.33) | 3/12 (25.00) | 0.18 |
| SD | 2/12 (16.67) | 6/12 (50.00) | ||
| PD* | 3/12 (25.00) | 2/12 (16.67) | ||
| NA | 0 (0.00) | 1/12 (8.33) | ||
| Clinical N2 downstaging | 3/12 (25.00) | 3/12 (25.00) | 1.00 | |
| Pathological N2 downstaging | 2/12 (16.67) | 3/12 (25.00) | 0.64 | |
| Resection | R0 | 3/6 (50.00) | 5/7 (71.43) | 0.59 |
| R1 | 3/6 (50.00) | 2/7 (28.57) |
Values are presented as n (percentage)
GC gemcitabine/carboplatin, RECIST Response Evaluation Criteria in Solid Tumors, PR partial response, SD stable disease, PD progressive disease, NA not available
*Two patients with the EGFR L858R mutation and the KRAS mutation or EML4-ALK translocation developed primary resistance to induction erlotinib